| Segment Information |
16. Segment Information
The Company’s reportable segments for operating income (loss) for the three months ended March 31, 2025 and 2024 consist of the following ($ in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2025 |
|
Journey |
|
Avenue |
|
Checkpoint |
|
Mustang |
|
Fortress1 |
|
Consolidated |
Product revenue, net |
|
$ |
13,139 |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
13,139 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of goods |
|
|
4,790 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
4,790 |
Intangible assets amortization |
|
|
1,065 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
1,065 |
Research and development |
|
|
39 |
|
|
411 |
|
|
3,788 |
|
|
(964) |
|
|
664 |
|
|
3,938 |
Selling, general and administrative |
|
|
10,569 |
|
|
1,494 |
|
|
7,361 |
|
|
1,217 |
|
|
5,022 |
|
|
25,663 |
Total operating expenses |
|
|
16,463 |
|
|
1,905 |
|
|
11,149 |
|
|
253 |
|
|
5,686 |
|
|
35,456 |
Loss from operations |
|
|
(3,324) |
|
|
(1,905) |
|
|
(11,149) |
|
|
(253) |
|
|
(5,686) |
|
|
(22,317) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
149 |
|
|
32 |
|
|
1 |
|
|
100 |
|
|
208 |
|
|
490 |
Interest expense and financing fee |
|
|
(891) |
|
|
— |
|
|
— |
|
|
— |
|
|
(1,914) |
|
|
(2,805) |
(Gain) loss on common stock warrant liabilities |
|
|
— |
|
|
15 |
|
|
(62) |
|
|
— |
|
|
— |
|
|
(47) |
Other income (expense) |
|
|
(7) |
|
|
— |
|
|
(2) |
|
|
— |
|
|
(3) |
|
|
(12) |
Total other income (expense) |
|
|
(749) |
|
|
47 |
|
|
(63) |
|
|
100 |
|
|
(1,709) |
|
|
(2,374) |
Segment net loss |
|
$ |
(4,073) |
|
$ |
(1,858) |
|
$ |
(11,212) |
|
$ |
(153) |
|
$ |
(7,395) |
|
$ |
(24,691) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to NCI |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,107 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to Fortress |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
(10,584) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intersegment activity2: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
$ |
— |
|
$ |
63 |
|
$ |
— |
|
$ |
63 |
|
$ |
(125) |
|
$ |
— |
Selling, general and administrative |
|
$ |
— |
|
$ |
117 |
|
$ |
178 |
|
$ |
279 |
|
$ |
(573) |
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Significant Items: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment assets |
|
$ |
84,963 |
|
$ |
3,593 |
|
$ |
34,165 |
|
$ |
14,909 |
|
$ |
40,440 |
|
$ |
178,071 |
Stock-based compensation - Research & development |
|
$ |
— |
|
$ |
40 |
|
$ |
689 |
|
$ |
(11) |
|
$ |
625 |
|
$ |
1,343 |
Stock-based compensation - Selling, general and administrative |
|
$ |
1,323 |
|
$ |
145 |
|
$ |
1,267 |
|
$ |
50 |
|
$ |
2,161 |
|
$ |
4,946 |
Note 1: Includes Fortress and private subsidiaries primarily funded by Fortress, including Cellvation, Cyprium, Helocyte, Oncogenuity and Urica; and intercompany eliminations.
Note 2: Segment activity consists of PIK Dividends and MSA and equity fees paid by the subsidiaries to Fortress, see Note 15.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2024 |
|
Journey |
|
Avenue |
|
Checkpoint |
|
Mustang |
|
Fortress1 |
|
Consolidated |
Product revenue, net |
|
$ |
13,030 |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
13,030 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of goods |
|
|
6,002 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
6,002 |
Intangible assets amortization |
|
|
814 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
814 |
Research and development |
|
|
7,884 |
|
|
2,392 |
|
|
8,497 |
|
|
3,804 |
|
|
2,262 |
|
|
24,839 |
Selling, general and administrative |
|
|
8,420 |
|
|
1,316 |
|
|
2,451 |
|
|
1,427 |
|
|
4,327 |
|
|
17,941 |
Asset impairment |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
Total operating expenses |
|
|
23,120 |
|
|
3,708 |
|
|
10,948 |
|
|
5,231 |
|
|
6,589 |
|
|
49,596 |
Loss from operations |
|
|
(10,090) |
|
|
(3,708) |
|
|
(10,948) |
|
|
(5,231) |
|
|
(6,589) |
|
|
(36,566) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
217 |
|
|
49 |
|
|
4 |
|
|
40 |
|
|
523 |
|
|
833 |
Interest expense and financing fee |
|
|
(548) |
|
|
— |
|
|
— |
|
|
— |
|
|
(2,054) |
|
|
(2,602) |
(Gain) loss on common stock warrant liabilities |
|
|
— |
|
|
(690) |
|
|
— |
|
|
— |
|
|
23 |
|
|
(667) |
Other income (expense) |
|
|
(21) |
|
|
— |
|
|
(1) |
|
|
— |
|
|
1 |
|
|
(21) |
Total other income (expense) |
|
|
(352) |
|
|
(641) |
|
|
3 |
|
|
40 |
|
|
(1,507) |
|
|
(2,457) |
Segment net loss |
|
$ |
(10,442) |
|
$ |
(4,349) |
|
$ |
(10,945) |
|
$ |
(5,191) |
|
$ |
(8,096) |
|
$ |
(39,023) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to NCI |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23,606 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to Fortress |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
(15,417) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intersegment activity2: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
$ |
— |
|
$ |
63 |
|
$ |
— |
|
$ |
63 |
|
$ |
(125) |
|
$ |
— |
Selling, general and administrative |
|
$ |
— |
|
$ |
71 |
|
$ |
521 |
|
$ |
63 |
|
$ |
(654) |
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Significant Items: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment assets |
|
$ |
66,571 |
|
$ |
3,309 |
|
$ |
11,975 |
|
$ |
14,592 |
|
$ |
68,198 |
|
$ |
164,645 |
Stock-based compensation - Research & development |
|
$ |
145 |
|
$ |
45 |
|
$ |
490 |
|
$ |
29 |
|
$ |
408 |
|
$ |
1,117 |
Stock-based compensation - Selling, general and administrative |
|
$ |
1,261 |
|
$ |
146 |
|
$ |
220 |
|
$ |
47 |
|
$ |
2,066 |
|
$ |
3,740 |
Note 1: Includes Fortress and private subsidiaries primarily funded by Fortress, including Cellvation, Cyprium, Helocyte, Oncogenuity and Urica; and intercompany eliminations.
Note 2: Segment activity consists of PIK Dividends and MSA and equity fees paid by the subsidiaries to Fortress, see Note 15.
|